Johnson & Johnson said on Tuesday its Covid-19 vaccine helped boost overall sales in its latest quarter, but the company is suspending its full-year guidance on sales of the vaccine, saying there is a surplus global supply and demand is uncertain.
The health products company sold $457 million of its Covid-19 vaccine in its most recent quarter, with international buyers accounting for most of those sales. In the same period a year earlier, shortly after the injection was authorized in the United States, the company’s Covid-19 vaccine sales were $100 million, exclusively in the United States. United. In the prior quarter, the company’s worldwide Covid-19 vaccine sales were $1.62 billion.